Unresectable Renal Cell Carcinoma Recruiting Phase 2 Trials for Cabozantinib (DB08875)

IndicationStatusPhase
DBCOND0115886 (Unresectable Renal Cell Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs